Port Delivery System With Ranibizumab: As Always - Risks Versus Benefits for the Recipients

Ophthalmic Surg Lasers Imaging Retina. 2022 Aug;53(8):416-417. doi: 10.3928/23258160-20220713-01. Epub 2022 Aug 1.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Choroidal Neovascularization* / drug therapy
  • Humans
  • Intravitreal Injections
  • Ranibizumab* / therapeutic use
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Ranibizumab